Quinupristin
Synercid (quinupristin) is a small molecule pharmaceutical. Quinupristin was first approved as Synercid on 1999-09-21. It is used to treat bacterial infections, staphylococcal infections, and streptococcal infections in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
Trade Name
FDA
EMA
Combinations
Synercid
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dalfopristin
+
Quinupristin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SYNERCID | King Pharmaceuticals | N-050748 RX | 1999-09-21 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| synercid | New Drug Application | 2019-08-07 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J2770 | Injection, quinupristin/dalfopristin, 500 mg (150/350) |
Clinical
Clinical Trials
39 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pseudobulbar palsy | D020828 | EFO_1001131 | — | — | 1 | 3 | — | 4 | |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | 1 | 1 | — | 3 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | 1 | 1 | — | 2 |
| Traumatic brain injuries | D000070642 | S06 | — | — | 1 | 1 | — | 2 | |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | 1 | 1 | — | 2 |
| Dementia | D003704 | F03 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | 1 | 4 | — | — | 4 |
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | 1 | 2 | 1 | — | — | 3 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 3 | — | — | 3 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | 3 | — | — | 3 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | 1 | — | — | 2 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 1 | 1 | — | — | 2 |
| Ventricular fibrillation | D014693 | EFO_0004287 | I49.01 | — | — | 2 | — | — | 2 |
| Huntington disease | D006816 | G10 | — | — | 1 | — | — | 1 | |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | 1 | — | — | 1 |
| Heart arrest | D006323 | EFO_0009492 | I46 | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 1 | 1 | — | — | — | 2 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | 1 | — | — | — | 1 |
| Treatment-resistant depressive disorder | D061218 | — | 1 | — | — | — | 1 | ||
| Dyskinesias | D020820 | G24 | — | 1 | — | — | — | 1 | |
| Autistic disorder | D001321 | EFO_0003758 | F84.0 | — | 1 | — | — | — | 1 |
| Neuralgia | D009437 | EFO_0009430 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 8 | — | — | — | — | 8 | ||
| Hepatitis b | D006509 | 1 | — | — | — | — | 1 | ||
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | — | — | — | — | 1 |
| Constipation | D003248 | HP_0002019 | K59.0 | 1 | — | — | — | — | 1 |
| Covid-19 | D000086382 | U07.1 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | QUINUPRISTIN |
| INN | quinupristin |
| Description | Quinupristin is a streptogramin B antibiotic, used in combination with dalfopristin under the trade name Synercid. It has activity against Gram-positive and atypical bacteria but not Gram-negative bacteria. It inhibits bacterial protein synthesis. The combination of quinupristin and dalfopristin is not active against Enterococcus faecalis and needs to be given in combination with other antibacterials for mixed infections that involve Gram-negative organisms.
|
| Classification | Small molecule |
| Drug class | steriodal compounds acting on progesterone receptors (excluding-gest- compounds); antibacterials, pristinamycin derivatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC[C@H]1NC(=O)[C@@H](NC(=O)c2ncccc2O)[C@@H](C)OC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2CC(=O)[C@H](CS[C@@H]3CN4CCC3CC4)CN2C(=O)[C@H](Cc2ccc(N(C)C)cc2)N(C)C(=O)[C@@H]2CCCN2C1=O |
Identifiers
| PDB | — |
| CAS-ID | 120138-50-3 |
| RxCUI | 229367 |
| ChEMBL ID | CHEMBL1200649 |
| ChEBI ID | — |
| PubChem CID | 5388937 |
| DrugBank | DB01369 |
| UNII ID | 23OW28RS7P (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,947 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,802 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more